Dihomo-γ-Linolenic Acid-d6

Dihomo-γ-Linolenic Acid-d₆ (DGLA-d₆) contains six deuterium atoms at the 8, 9, 11, 12, 14, and 15 positions. It is intended for use as an internal standard for the quantification of DGLA by GC- or LC-mass spectrometry. Dihomo-γ-Linolenic Acid (DGLA, 20:3), an elongation product of γ-linolenic acid (18:3), is rapidly metabolized by fatty acid desaturases to produce arachidonic acid (20:4). DGLA is metabolized through the cyclooxygenase pathway to produce 1-series prostaglandins, (PGs), including PGE₁.^1,2 In mice, DGLA supplementation in the diet can reduce atopic dermatitis and atherosclerosis.^3,4

1.Bell, J.G., Tocher, D.R., and Sargent, J.R.Effect of supplementation with 20:3(n-3), 20:4(n-6) and 20:5(n-3) on the production of prostaglandins E and F of the 1-, 2- and 3-series in turbot (Scophthalmus maximus) brain astroglial cells in primary cultureBiochimica et Biophysica Acta1211335-342(1994) 2.Levin, G., Duffin, K.L., Obukowicz, M.G., et al.Differential metabolism of dihomo-γ-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: Implications for cellular synthesis of prostaglandin E1 and prostaglandin E2Biochemistry Journal365489-496(2002) 3.Kawashima, H., Tateishi, N., Shiraishi, A., et al.Oral administration of dihomo-γ-linolenic acid prevents development of atopic dermatitis in NC/Nga miceLipids43(1)37-43(2007) 4.Takai, S., Jin, D., Kawashima, H., et al.Anti-atherosclerotic effects of dihomo-γ-linolenic acid in ApoE-deficient miceJ.Atheroscer.Thromb.16(4)480-489(2009)